This is the authors' abstract. We don't add key points for this paper.
The so-called reproducibility crisis in biomedical science did not originate in academia but in the sloppy practices and sanctimonious posturing of industry labs. In 2011, Bayer claimed that only 20%–25% of drug target findings could be reproduced, and in 2012, Amgen alleged that only 6 of 53 “landmark” cancer studies were confirmable—yet both papers withheld the crucial evidence: which studies, what methods, and what criteria. These unsubstantiated indictments became gospel, spawning NIH’s 2015 “Rigor & Reproducibility” mandate, a sprawling bureaucracy of compliance language, checklists, and paperwork. Meanwhile, more transparent efforts such as the Reproducibility Project: Cancer Biology revealed a far more nuanced picture: some studies replicate, some do not, and biology is often complex. Inflated economic scare claims, such as the $28 billion “waste” estimate, further fueled the panic despite shaky assumptions. The outcome is perverse: academic scientists who most often blind, repeat, and verify their work are now punished with paperwork, while the industrial culprits escape scrutiny. The crisis, then, is not a scientific failure but a failure of judgment: industry soundbites amplified by NIH gullibility into a decade of bureaucratic theater.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Martin L. Yarmush (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: